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Abstract
We report an early onset spastic ataxia-neuropathy syndrome in two brothers of a consanguineous family characterized
clinically by lower extremity spasticity, peripheral neuropathy, ptosis, oculomotor apraxia, dystonia, cerebellar atrophy, and
progressive myoclonic epilepsy. Whole-exome sequencing identified a homozygous missense mutation (c.1847G.A;
p.Y616C) in AFG3L2, encoding a subunit of an m-AAA protease. m-AAA proteases reside in the mitochondrial inner
membrane and are responsible for removal of damaged or misfolded proteins and proteolytic activation of essential
mitochondrial proteins. AFG3L2 forms either a homo-oligomeric isoenzyme or a hetero-oligomeric complex with
paraplegin, a homologous protein mutated in hereditary spastic paraplegia type 7 (SPG7). Heterozygous loss-of-function
mutations in AFG3L2 cause autosomal-dominant spinocerebellar ataxia type 28 (SCA28), a disorder whose phenotype is
strikingly different from that of our patients. As defined in yeast complementation assays, the AFG3L2
Y616C gene product is a
hypomorphic variant that exhibited oligomerization defects in yeast as well as in patient fibroblasts. Specifically, the
formation of AFG3L2
Y616C complexes was impaired, both with itself and to a greater extent with paraplegin. This produced
an early-onset clinical syndrome that combines the severe phenotypes of SPG7 and SCA28, in additional to other
‘‘mitochondrial’’ features such as oculomotor apraxia, extrapyramidal dysfunction, and myoclonic epilepsy. These findings
expand the phenotype associated with AFG3L2 mutations and suggest that AFG3L2-related disease should be considered in
the differential diagnosis of spastic ataxias.
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Introduction
AFG3L2 encodes a subunit of the m-AAA class of mitochondrial
proteases [1,2]. These ATP-dependent metallopeptidases assemble
into large proteolytic complexes in the inner membrane of
mitochondria and function to ensure mitochondrial protein quality
control through the degradation of misfolded proteins and the
maturation of essential proteins [3]. In humans, m-AAA proteases
assemble into different isoenzymes: homo-oligomeric complexes of
AFG3L2 subunits or hetero-oligomeric complexes of AFG3L2
with paraplegin (encoded by SPG7). Notably, paraplegin is
incapable of self-assembling into homo-oligomers and requires
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dominant spinocerebellar ataxia 28 (SCA28; MIM #610246), a
recently recognized and rare disorder characterized clinically by
adult-onset dysarthria, ptosis and cerebellar ataxia [1,4,5].
Mutations in SPG7, on the other hand, are associated with
another type of m-AAA-associated neurological disease, autosomal
recessive hereditary spastic paraplegia type 7 (SPG7; MIM
#607259). This disorder is characterized by adult-onset spasticity
and weakness of the lower extremities due to a length-dependent
axonopathy of corticospinal motor neurons [6,7]. The phenotypic
variation between these two disorders is particularly remarkable
since these proteins are m-AAA protease subunits that interact with
one another.
Transgenic mouse models have been informative in character-
izing the functional role of m-AAA complexes in human disease.
While Spg7
+/- mice are normal, Spg7
-/- null mice accurately
phenocopy human SPG7 with a late-onset impairment of motor
performance and degeneration of long spinal and peripheral axons
[8]. Afg3l2
-/- null mice, which have no human counterpart to date,
exhibit a severe neurodegenerative phenotype associated with
deficient axonal radial growth and delayed myelination, resulting
in poor central and peripheral axonal development [1,9]. These
mice develop hind limb paresis by P7, which progresses to
complete paralysis and death by P16 [1]. Predictably, Afg3l2
+/-
mice have late-onset progressive motor incoordination and
Purkinje cell degeneration similar to human SCA28 [1,9]. Of
particular interest, double mutant Spg7
-/-Afg3l2
+/- mice exhibit a
unique phenotype with severe early-onset spasticity and impair-
ment of cerebellar function that is associated with axonal and
cerebellar degeneration. This latter result reflects the accelerated
progression of each phenotype and indicates that decreased dosage
of both proteins could have a synergistic effect on the expression of
these respective disorders [10]. Similar alterations in the dosage of
m-AAA activity in humans would be predicted to have comparable
phenotypic findings.
We now describe two teenage brothers, of a consanguineous
family, with a novel homozygous missense mutation in AFG3L2
initially identified by whole exome sequencing (WES). Yeast
studies demonstrate that this mutation decreases cellular m-AAA
activity due to impaired oligomerization with itself as well as with
paraplegin. As a result, our patients present with an early-onset
phenotype combining features of SPG7 and SCA28 resembling
the accelerated phenotype seen in compound Spg7
-/-Afg3l2
+/-
mice. Furthermore, the brothers have the additional findings of
oculomotor apraxia, dystonia, and progressive myoclonic epilepsy,
which are common features in mitochondrial disorders and likely
result from reduced m-AAA activity in other regions of the CNS.
Our findings expand the spectrum of neurological features
associated with defective m-AAA protease activity, and highlight
the phenotypic variation of m-AAA disorders as a result of the type
of mutation and subunit involved.
Results
Patient examination and genetic evaluation
The parents of the two affected brothers were first cousins of
Hispanic origin with no family history for neurodegenerative
disease (Figure 1A). The siblings were born thirteen months apart
in Colombia without complications. Their disease courses were
similar, with the younger sibling’s being more severe. The older
brother (IV-1) had normal development until exhibiting a spastic
gait in his second year. The younger brother (IV-2) never
ambulated independently. At eight years of age, each developed
progressive myoclonic epilepsy with stimulus-induced myoclonus
associated with generalized tonic-clonic and myoclonic seizures.
This was followed by progressive dysarthria, dysphagia, and motor
degeneration, with the older sibling eventually losing his ability to
ambulate. Both subsequently developed lower extremity weakness
and distal muscle atrophy.
IV-2 died at 13 years of age from pneumonia-related
complications, and our evaluation was limited to other physician’s
notes and genetic evaluation. IV-1’s examination revealed spastic
paraparesis in the lower extremities as well as appendicular
dysmetria, dysdiadochokinesia, and ataxic dysarthria. He also had
decreased muscle bulk and strength in his lower extremities.
Additional findings included ptosis, oculomotor apraxia, dystonic
movements, and stimulus-induced myoclonus. Fundoscopic and
ophthalmological exams were unremarkable. His cognition was
normal. In addition, both parents were without neurological
complaints and had normal neurological and ophthalmological
exams.
Diagnostic testing of IV-1 revealed multiple abnormalities
(Table 1). Brain MRI without contrast revealed moderate
cerebellar atrophy (Figure 2A). Nerve conduction studies showed
an axonal sensorimotor neuropathy affecting his lower extremities,
and sural nerve biopsy revealed mild ‘‘onion bulbing’’ suggestive
of a mild chronic demyelinating/remyelinating process. Muscle
biopsy histology by light microscopy was within normal limits and
without ragged red fibers; however, transmission electron
microscopy revealed misplaced mitochondria associated with large
lipid droplets. Muscle samples also had decreased mtDNA copy
number. Finally, an electroencephalogram was consistent with
progressive myoclonic epilepsy (Table 1). His parents underwent a
less extensive evaluation. Parental nerve conduction studies were
normal. Brain MRIs revealed that the father (III-1; 58 years old)
was within normal limits; however, the mother (III-2; 39 years old)
had mild cerebellar atrophy (Figure 2B).
Since prior genetic testing had not yielded a diagnosis (see
Materials and Methods), we performed WES to search for
Author Summary
Mitochondria are cellular organelles important for con-
verting sugar or fats into energy that cells can use for their
functions and survival. Many neurological diseases are the
result of mitochondrial dysfunction as affected cells are
unable to cope with lowered energy supplies and
increased oxidative stress. These deficiencies cause accu-
mulation of cellular damage and eventually cell death.
Spastic ataxias are neurological disorders involving cells
with large energy requirements, the cerebellar Purkinje
cells and the cerebral upper motor neurons. When these
cells function improperly or die, individuals develop
symptoms of incoordination (ataxia) and abnormal muscle
tone in their legs (spastic paraplegia). Using emerging
techniques of whole-exome sequencing we discovered
that homozygous mutations in the AFG3L2 gene caused
spastic ataxia in two brothers of a consanguineous family.
AFG3L2 encodes a subunit of mitochondrial matrix
proteases (m-AAA proteases) that regulate the functional
integrity of mitochondria. Heterozygous mutations in
AFG3L2 were previously found to cause a disorder
involving the Purkinje cells of the cerebellum resulting in
ataxia. Interestingly, another isoform of m-AAA proteases
consists of AFG3L2 complexing with paraplegin, a similar
protein associated with a hereditary spastic paraplegia.
Our analysis provides insight into why different mutations
in m-AAA protease subunits cause different neurological
disorders.
AFG3L2 and Spastic Ataxia-Neuropathy Syndrome
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were evaluated and filtered using several methods including their
presence or absence in dbSNP, segregation analysis, and the
estimation of pathogenic potential using amino-acid conservation
programs (see Materials and Methods and Tables S1, S2, S3)[13].
An average of 8585 missense and 87 nonsense changes were
identified in each family member tested. The presence of
consanguinity and the fact that the parents appeared largely
asymptomatic suggested that the patients would likely be
homozygous for any disease-causing mutations, and therefore a
homozygous autosomal-recessive model was applied. Final analysis
yielded two variant-containing candidate genes that fulfilled our
selection criteria (Table S3). One candidate gene, DMGDH,
encoding dimethylglycine dehydrogenase (MIM #605850), was
previously associated with a syndrome of elevated serum creatine
kinase and an unusual fish-like body odor [14,15]. This was not
consistent with the siblings’ phenotype. The other candidate gene,
AFG3L2, had recently been associated with autosomal-dominant
SCA28 [2,4,5]. Because the brothers had the features of a
cerebellar ataxia, we considered the homozygous AFG3L2
Figure 1. Genetic analysis of family with early onset spastic ataxia-neuropathy syndrome. (A) Pedigree of family. (B) Sequencing of the
c.1847G.A; p.Y616C AFG3L2 mutation in family members. (C) Alignment of amino acid sequences from AFG3L2 of several vertebrate species
indicates that Y616 and the flanking residues are highly conserved.
doi:10.1371/journal.pgen.1002325.g001
Table 1. Clinical and Laboratory Data for Patient IV-1.
Diagnostic Evaluation Results
Brain MRI Moderate cerebellar/pontine atrophy, mild thinning of corpus callosum otherwise the supratentorial brain was
unremarkable.
Brain MR Spectroscopy Low NAA values in pons and cerebellum.
Nerve conduction studies Axonal sensorimotor peripheral neuropathy in bilateral lower extremities; upper extremity testing was normal.
Electromyography
(left tibialis anterior)
Membrane irritability, representing active denervation, and polyphasic motor units representing denervation/
reinnervation
Sural nerve biopsy Chronic demyelination/remylination process represented by mild onion bulbing (Schwann cell processes around a
central axon). There was also focal small axonal sprouting suggestive of axonal regeneration.
Skeletal muscle biopsy Relatively normal structure and biochemical staining. Transmission electron microscopy evaluation revealed an
increased number of lipid droplets between the myofibrils and sarcolemmal region that were often associated
with mitochondria. Mitochondria showed variation in shape and size including elongated morphology.
Skeletal muscle mtDNA copy number 2161 (normal 2951-4427)
Electroencephalogram Diffuse slowing/disorganization, fronto-central spike/waves, and myoclonic stimulus-induced seizures during
photic stimulation.
doi:10.1371/journal.pgen.1002325.t001
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variant consisted of a c.1847A.G mutation in exon 15, which
resulted in the missense change, p.Y616C (Figure 1B). This
tyrosine residue is located at the beginning of the proteolytic
domain and is highly conserved among vertebrates, including
mouse, chicken, frog, lizard, and stickleback (Figure 1C)[16].
AFG3L2
Y616C is functionally impaired, but retains ATPase
and proteolytic activities
Previous studies have shown that yeast is a useful model system
to assess the functional activity of human m-AAA proteases and to
investigate in detail the pathogenic mechanisms of mutations in m-
AAA protease subunits [17]. m-AAA proteases are evolutionarily
conserved, with S. cerevisiae possessing only hetero-oligomeric m-
AAA protease complexes composed of Yta10 and Yta12 subunits.
These proteins can be substituted with the human orthologues in
order to study their respective chemistries. Yeast cells lacking
Yta10 and Yta12 (Dyta10Dyta12 cells) are incapable of proteolyt-
ically processing the nuclear-encoded mitochondrial protein
MrpL32, a component of mitochondrial ribosomes. Impaired
ribosome assembly in the absence of the m-AAA protease abolishes
the synthesis of mitochondrial-encoded respiratory chain subunits
and impairs aerobic respiration [18]. Thus, the activity of m-AAA
proteases in yeast cells can be monitored either directly, by western
blot analysis of the conversion of MrpL32 from its precursor to its
mature form, or indirectly, by assessing respiratory growth on non-
fermentable carbon sources such as glycerol [17,19].
m-AAA proteases form hexameric complexes [20]. Two
isoforms can be distinguished in human mitochondria: a homo-
oligomeric form comprised of AFG3L2 subunits and a hetero-
oligomeric form containing AFG3L2 and paraplegin subunits in
equimolar ratios. We examined the functional activity of
AFG3L2
Y616C in the context of both isoenzymes. Expression of
only human AFG3L2 in Dyta10Dyta12 cells restores maturation of
MrpL32 and respiratory growth on glycerol-containing media,
demonstrating functional conservation of yeast and homo-
oligomeric human m-AAA proteases (Figure 3A, 3B) [17,19].
Remarkably, expression of AFG3L2
Y616C impaired processing of
MrpL32 in comparison to cells harboring AFG3L2 (Figure 3A).
However, maturation was not completely inhibited, which allowed
for some respiratory growth of Dyta10Dyta12 cells (Figure 3B). We
conclude that the Y616 mutation of AFG3L2 interferes with, but
does not completely inhibit, the activity of the homo-oligomeric m-
AAA protease.
Respiratory growth of yeast cells and MrpL32 processing depend
on both ATPase and proteolytic activities of the m-AAA protease.
Mutations of the Walker A site of AFG3L2’s AAA domain (K354A)
or within its proteolytic center (E575Q) inactivated the homo-
oligomeric protease and abolished respiratory growth (Figure 3B).
In order to directly monitor both activities of the AFG3L2
Y616C
variant, we exploited our previous observation that functional
deficiencies in individual domains of m-AAA protease subunits can
be complemented by the presence of wild-type domains in other
subunits of the assembled m-AAA ring complexes [21]. In other
words, assembled m-AAA protease complexes composed of wild-
type and inactive mutant subunits are functionally active [21]. Co-
expression of AFG3L2 with AFG3L2
Y616C in Dyta10Dyta12 cells
substantially increased MrpL32 processing and respiratory growth
when compared to cells expressing only AFG3L2
Y616C (Figure 3A,
3B). MrpL32 processing and respiratory growth of Dyta10Dyta12
cells were restored to a similar extent upon co-expression of
AFG3L2
Y616C with either of the two inactive AFG3L2 variants
(AFG3L2
K354A or AFG3L2
E575Q) (Figure 3A, 3B). As the
AFG3L2
K354A and AFG3L2
E575Q subunits lack ATPase and
proteolytic activity, respectively, and are functionally inactive as
homo-oligomeric complexes, the significantly improved MrpL32
processing and respiratory growth upon co-expression with
AFG3L2
Y616C indicates intersubunit complementation of both
ATPase and proteolytic activities [21].
These experiments demonstrate that homo-oligomeric m-AAA
protease complexes composed of AFG3L2
Y616C subunits are
functionally impaired, but retain both ATPase and proteolytic
activities. We conclude that AFG3L2
Y616C is not a loss-of-function
mutant, but appears to be hypomorphic. This is in striking
contrast to AFG3L2 mutations causing SCA28 that fail to process
MrpL32 and do not promote respiratory growth in Dyta10Dyta12
cells [2].
AFG3L2
Y616C affects the activity of hetero-oligomeric m-
AAA proteases containing paraplegin
To examine the functional activity of AFG3L2
Y616C in the
context of the hetero-oligomeric m-AAA isoenzyme, we co-
expressed AFG3L2
Y616C with paraplegin or an inactive variant
harboring a mutation in the ATPase domain (SPG7
K355A)i n
Dyta10Dyta12 cells. We observed MrpL32 processing (Figure 3C)
and respiratory growth (Figure 3D), indicating the presence of
functionallyactivem-AAA proteaseinthesecells.Theinterpretation
oftheseexperiments,however,iscomplex,sinceAFG3L2
Y616Cmay
self-assemble and/or co-assemble with paraplegin. Thus, it cannot
be distinguished whether respiratory growth is maintained by
homo-oligomeric AFG3L2
Y616C complexes or by hetero-oligomeric
m-AAA proteases composed of AFG3L2
Y616C and paraplegin.
We therefore introduced a point mutation in the proteolytic
domains of AFG3L2 (AFG3L2
E575Q) and AFG3L2
Y616C (AF-
Figure 2. Neuroimaging of family members. T1 sagittal magnetic resonance imaging of the brain of IV-2 (A) reveals notable cerebellar atrophy.
His asymptomatic mother, III-2 (B), has mild cerebellar atrophy, while his asymptomatic father, III-1 (C) has normal imaging.
doi:10.1371/journal.pgen.1002325.g002
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Y616C/E575Q). This mutation renders each variant of AFG3L2
proteolytically inactive and abolishes their ability to restore
respiratory growth of Dyta10Dyta12 cells (Figure 3D) [17,19].
However,whenAFG3L2
E575Qand parapleginwereco-expressedin
Dyta10Dyta12 cells, respiratory growth was restored (Figure 3D)
[17,19]. This is due to paraplegin, which is unable to self-assemble,
forming hetero-oligomeric complexes with AFG3L2
E575Q;i nt h i s
context, paraplegin provides the proteolytic activity within the m-
AAA protease ring complexes through intersubunit complementa-
tion [19,21]. In stark contrast to these results with AFG3L2
E575Q,
AFG3L2
Y616C/E575Q did not allow respiratory growth when co-
expressed with paraplegin (Figure 3B), indicating that the activity of
the AFG3L2
Y616C variant is impaired in the context of a hetero-
oligomeric m-AAA isoenzyme with paraplegin.
Impaired assembly of AFG3L2
Y616C into m-AAA protease
complexes
Amino acid Y616 is located in close proximity to the protomer
interface in structural models of hexameric m-AAA protease ring
complexes [2,20]. Interestingly, amino acid residues in close
proximity to this region are involved in oligomerization of yeast m-
AAA proteases [20]. We therefore assessed the assembly of
AFG3L2
Y616C with itself or with paraplegin in Dyta10Dyta12 cells.
Mitochondrial extracts were isolated from Dyta10Dyta12 cells
expressing different AFG3L2 variants alone or in combination
with paraplegin and analyzed by blue native-polyacrylamide gel
electrophoresis (BN-PAGE)(Figure 4A). When compared to
AFG3L2, the assembly of AFG3L2
Y616C with paraplegin was
severely inhibited, while the formation of AFG3L2
Y616C homo-
oligomers was impaired to a consistently lesser degree (Figure 4A).
To further substantiate these results, mitoplasts (isolated
mitochondria without their outer membranes) were prepared
from primary skin fibroblasts from family members and used to
test the stability of AFG3L2
Y616C, as well as its assembly into
homo-oligomeric or hetero-oligomeric m-AAA complexes. AF-
G3L2
Y616C and paraplegin are present at normal levels in patient
fibroblasts both in the soluble and pellet fractions, demonstrating
that the mutation does not affect the solubility or the stability of
the AFG3L2 protein (Figure 4B). However, BN-PAGE analysis of
Figure 3. MrpL32 maturation and yeast complementation assays for the evaluation of AFG3L2
Y616C activity. (A) Protein expression of
AFG3L2 in Dyta10Dyta12 cells was analyzed by SDS-PAGE and immunoblotting using AFG3L2-specific antibodies. Maturation of MrpL32, a substrate
of m-AAA proteases, was monitored in isolated mitochondria by immunoblotting using polyclonal antisera directed against MrpL32. The outer
membrane protein Tom20 was used as a loading control. (B) Respiratory growth of Dyta10Dyta12 cells expressing human m-AAA protease subunits.
To assess the functional activity of homo-oligomeric m-AAA proteases, AFG3L2
Y616C was expressed in Dyta10Dyta12 cells alone or co-expressed with
AFG3L2, AFG3L2
E575Q (proteolytic site mutant) or AFG3L2
K354A (ATPase domain-Walker A motif mutant) where indicated. Cell growth was analyzed at
30uC on glucose- (YPD) or glycerol containing (YPG) media. (C) Protein expression and maturation of MrpL32 were monitored in Dyta10Dyta12 cells
expressing the indicated variants of human m-AAA protease subunits as in (A). (D) To monitor the activity of hetero-oligomeric m-AAA complexes,
AFG3L2
Y616C and AFG3L2
Y616C/E575Q were expressed with paraplegin (SPG7) or SPG7
K355A (Walker A motif mutant). Cell growth was analyzed at 30uC
on glucose- (YPD) or glycerol-containing (YPG) media.
doi:10.1371/journal.pgen.1002325.g003
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assembled AFG3L2-containing complexes in fibroblasts of patient
IV-1; moreover, hetero-oligomeric complexes harboring para-
plegin were drastically reduced (Figure 4C). Consistent with these
findings, the heterozygous parents displayed intermediate levels of
assembled complexes (Figure 4C). Furthermore, these results are
Figure 4. Assembly of AFG3L2, AFG3L2
Y616C, and AFG3L2
Y616C/E575Q in mitochondria. (A) Mitochondrial extracts (100 mg protein)
harbouring AFG3L2 (and variants thereof) and paraplegin (SPG7) as indicated were isolated from Dyta10Dyta12 cells and solubilized with digitonin
(1% (w/v)) at a concentration of 5 mg/ml. Extracts were analyzed by BN-PAGE, transferred onto a PVDF membrane and stained with Coomassie blue
G-250 (right panel). After destaining, the membrane was used for immunoblotting using AFG3L2- or SPG7-specific antibodies. The outer membrane
protein Tom40 was used as a loading control. Thyroglobulin (669 kDa) and apoferritin (440 kDa) were used for size calibration. (B) Mitoplasts were
prepared from primary fibroblasts of family members and solubilized with digitonin. Soluble and pellet fractions were analysed by SDS-PAGE using
AFG3L2- and paraplegin-specific antibodies. No alteration of the steady-state levels of the two proteins was observed in the proband (IV.1). (C) To
detect assembled m-AAA proteases in the patient cell line, the same preparations were analyzed by BN-PAGE using AFG3L2- or paraplegin-specific
antibodies. HSP60 was used for calibration. WT: wild-type; DD: Dyta10Dyta12; CVmon: complex V monomer; CVdim: complex V dimer; CIIIdim:
complex III dimer.
doi:10.1371/journal.pgen.1002325.g004
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Y616C, as this variant’s
targeting to mitochondria was not impaired when overexpressed in
cells (Figure S1).
Taken together, these experiments provide evidence that the
primary pathogenic process of AFG3L2
Y616C involves impaired
oligomerization with itself and paraplegin, leading to remarkably
low levels of functionally active m-AAA protease complexes.
Discussion
This study links an early onset spastic-ataxia-neuropathy
syndrome to a unique homozygous mutation in AFG3L2 in the
absence of any associated SPG7 mutations. Studies in yeast and
patient fibroblasts reveal that the AFG3L2
Y616C mutant is a
hypomorphic variant with reduced respiratory capability. This
reduction is a consequence of its impaired ability to undergo
oligomerization with itself or, in an even more pronounced
manner, with paraplegin. Recent experiments with yeast m-AAA
orthologues indicate a crucial role of the proteolytic domains for
protease assembly. Interestingly, within a structural model of m-
AAA proteases, the Y616 residue is in close proximity to amino
acids that determine hetero-oligomerization of the yeast ortholo-
gue and prevent its homo-oligomerization [20]. Nevertheless,
further interpretations regarding why the Y616C mutation has its
specific effects on AFG3L2 and paraplegin oligomerization are
difficult to make without the availability of crystal structures for
both homo- and hetero-oligomeric complexes. In the homozygous
context of our patients, the reduced levels of homo-oligomeric m-
AAA proteases and the almost complete absence of hetero-
oligomeric m-AAA isoenzymes explain the striking combination of
clinical features of both SPG7 and SCA28, including spastic
paraplegia, ptosis, and cerebellar ataxia [2,4,6,22].
These features could have been anticipated by the phenotype
of transgenic Afg3l2
+/-Spg7
-/- mice, whose similarly reduced
dosage of m-AAA activity produced a comparable syndrome.
Our genetic and biochemical findings were consistent with these
transgenic mouse models of m-AAA dysfunction and indicate a
critical role for the dosage of m-AAA protease activity in the
maintenance of neuronal functions. Homo- and hetero-oligomer-
ic m-AAA isoenzymes exhibit overlapping activities and can
partially substitute for each other [19]; however as seen in
Afg3l2
+/-Spg7
-/- mice, the combination of absent paraplegin and
deficient AFG3L2 creates a severe phenotype. Our patients’
features closely resemble those of the Afg3l2
+/-Spg7
-/- mice --
early-onset axonopathy and cerebellar degeneration, as well as
mitochondrial DNA depletion [10]. AFG3L2
Y616C, whose
assembly with paraplegin is impaired, may lead to an effective
loss of paraplegin function in the patients as paraplegin is unable
to self-assemble and requires oligomerization with AFG3L2 for
function. Mutations in this region of AFG3L2 may create a
similar combined effect, as seen in Afg3l2
+/-Spg7
-/- mice, of Spg7
deletion and Afg3l2 heterozygosity, i.e., the loss of hetero-
oligomeric m-AAA proteases containing paraplegin combined
with reduced levels of functional AFG3L2. The end result would
be decreased total m-AAA activity in affected neural cells
producing a combined SCA28/SPG7 phenotype.
Our patients also exhibit additional neurological findings seen in
other mitochondrial disorders, including oculomotor apraxia,
dystonia, and progressive myotonic epilepsy [23]. The presence
of these mitochondrial symptoms is consistent with the known
function of AFG3L2 and paraplegin in mitochondrial respiration.
Specifically, these proteins’ involvement in mitochondrial quality
control, i.e., the removal of misfolded or damaged mitochondrial
proteins and activation of proteins that are essential for aerobic
respiration [3]. Dystonia was previously observed in a family
whose affected members carried an 18p chromosomal deletion
that included AFG3L2 [24], and Afg3l2
+/-Spg7
-/- mice also
exhibited dystonic features [10]. The absence of our patients’
other additional mitochondrial symptoms in Afg3l2
+/-Spg7
-/- mice
means these mice were not an exact phenocopy; however, this may
be due to the compensatory effects of an additional murine m-AAA
protease subunit, Afg3l1, which has overlapping activities with
Afg3l2 [19,25]. Overall, it is likely that decreased m-AAA dosage
in regions of the CNS usually unaffected by SCA28 or SPG7 are
the cause of these features, but in a consanguineous family it is
important to remember other genes may be modifying the
phenotype.
Yeast complementation studies help explain the phenotypes of
all the members of our patients’ family. In the proband’s cells,
assembled m-AAA proteases were present at decreased levels. In
this respect, the AFG3L2
Y616C mutation behaved much differently
as compared to the previously described loss-of-function AFG3L2
variants associated with dominant SCA28 [2]. The decreased, but
present, functional activity of AFG3L2
Y616C likely explains the
lack of an obvious clinical phenotype in the heterozygous parents
of the affected patients. In their cells, the combined expression of
both the AFG3L2
Y616C and wild-type alleles appears to provide a
sufficient amount of m-AAA protease activity to overcome a
theoretical threshold for cerebellar disease. That threshold is likely
greater than 50% of normal activity, because most heterozygotes
for loss-of-function AFG3L2 mutations are symptomatic. However,
it should be recognized that previously reported SCA28 patients
had late-onset cerebellar ataxia and, although the brain MRI of
our proband’s father was within normal limits, the mother had
asymptomatic, mild cerebellar atrophy. This result indicates that it
remains to be seen whether any family member heterozygous for
AFG3L2
Y616C will develop neurological dysfunction later in life.
Analysis of the AFG3L2
Y616C mutation identified here, together
with data from transgenic mice and patients with either SCA28 or
SPG7, link a spectrum of neurological phenotypes to specific
mutations in m-AAA protease subunits. This spectrum includes:
homozygous loss-of-function mutations in SPG7 resulting in the
absence of hetero-oligomeric m-AAA isoenzymes (associated with
SPG7); heterozygous loss-of-function mutations in AFG3L2
decreasing the dosage of both homo- and hetero-oligomeric forms
of the m-AAA proteases (associated with SCA28); and homozygous
AFG3L2
Y616C mutations also affecting both isoforms and further
reducing the residual cellular m-AAA protease activity (associated
with the early-onset spastic ataxia-neuropathy syndrome described
here). Other genetic combinations of defective subunits could also
cause neurological dysfunction, with decreased dosage of m-AAA
activity resulting from various mixtures of heterozygous or
homozygous mutations in AFG3L2 and/or SPG7. The inheritance
could appear to be either autosomal recessive and/or dominant
indicating that genetic testing of AFG3L2 and SPG7 in any
individuals with spastic ataxia, whether or not mitochondrial
symptoms are present, may identify additional patients with m-
AAA-related neurological disease.
Although the presently described syndrome shares features with
SCA28 and prominent spasticity clearly extends the phenotypic
spectrum associated with AFG3L2 mutations, it appears different
from SCA28 in several ways, specifically: 1) much earlier onset of
symptoms, 2) spastic paraplegia as the earliest and predominant
feature, and 3) presence of a peripheral neuropathy. As SCA28 is
also identified with autosomal dominant inheritance, we feel that
the current syndrome is distinct and should be classified separately
as an AFG3L2-associated spastic-ataxia-neuropathy syndrome.
With the identification of other patients with similar phenotypes
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AFG3L2-related disorders and whether other mutations in
AFG3L2 and SPG7 will only cause a spastic-ataxia-neuropathy
syndrome or consistently produce an expanded ‘‘PME-spastic-
ataxia-neuropathy’’ syndrome.
Materials and Methods
Ethics statement
Clinical and laboratory studies were approved by the NHGRI
IRB. Patients and family members who were enrolled in the
clinical protocol gave written informed consent, specifically
including WES.
Relevant previous genetic and metabolic workup
Sanger sequencing of the following genes was within normal
limits: SPG7, CLN8, COX10, DLD, EPM1, EPM2A, EPM2B,
PANK2, PLA2G6, PRICKLE1, SCO1, SCO2, SURF1, as was an
analysis of mtDNA for point mutations, deletions and duplications.
A lysosomal enzyme panel and buffy coat electron microscopy
were also normal.
DNA samples
Genomic DNA was extracted from peripheral whole blood,
using the Gentra Puregene Blood kit (Qiagen) per manufacturer’s
standards. An additional chloroform-phenol extraction step was
carried out to neutralize infectious agents.
Genotyping
Illumina HumanOmni1-Quad genotyping arrays were run for
one affected child and parents. The deceased brother’s DNA was
not analyzed on the SNP chip due to sample limitations. Analyses
including homozygosity mapping were carried out using Illumina
GenomeStudio Software. SNP chip data were also used to verify
exome sample IDs for quality control purposes, and to calculate
sensitivity and specificity for genotype calling in exome sequence
data.
Next-generation sequencing and variant analysis
Solution hybridization exome capture was carried out using the
Sureselect Human All exon System (Agilent Technologies, Santa
Clara, CA). This technique uses biotinylated RNA baits to
hybridize to sequences that correspond to exons [26]. Manufac-
turer’s protocol version 1.0 compatible with Illumina paired-end
sequencing was used, with the exception that DNA fragment size
and quality was measured using a 2% agarose gel stained with
Sybr Gold instead of using an Agilent Bioanalyser. The
manufacturer’s specifications state that the capture regions total
approximately 38 Mb. This kit covers the 1.22% of the human
genome corresponding to the Consensus Conserved Domain
Sequences database (CCDS) and greater than 1000 non-coding
RNAs. Flowcell preparation and 76bp paired end read sequencing
were carried out as per protocol for the GAIIx sequencer (Illumina
Inc, San Diego CA)[27]. Approximately two lanes on a GAIIx
flowcell were used per exome sample to generate sufficient reads to
generate the aligned sequence.
Image analysis and base calling on all lanes of data were
performed using Illumina Genome Analyzer Pipeline software
(GAPipeline versions 1.4.0 or greater) with default parameters.
The complexity of sequencing libraries was between 97.5%–
99.3%. Complexity is the percentage of unique molecules
determined from the first 25 bp in single-fragment reads and the
combination of the first 25 bp in both paired-end reads out of total
number of reads where the match chromosome field is not ‘‘QC’’
and the first 25 bp have no ‘N’s.
Read mapping, variant calling, and annotation
Reads were aligned to a human reference sequence (UCSC
assembly hg18, NCBI build 36) using the package called ‘‘efficient
large-scale alignment of nucleotide databases’’ (ELAND). Reads
that aligned uniquely were grouped into genomic sequence
intervals of about 100 kb, and reads that failed to align were
binned with their paired-end mates. Reads in each bin were
subjected to a Smith-Waterman-based local alignment algorithm,
cross_match using the parameters–minscore 21 and –mask level 0 to
their respective 100kb genomic sequence (http://www.phrap.org).
A total of 3.04–3.53 Gb of high-confidence mappable sequence
data were generated in autosomal targeted regions per individual
(Table S1). Genotypes were called at all positions where there were
high-quality sequence bases (Phred-like Q20 or greater) using a
Bayesian algorithm (Most Probable Genotype – MPG; Nancy F
Hansen, unpublished observations). The genotype calls were
compared against Illumina Human 1M-Quad genotype chips.
Genotypes with a MPG score of 10 or greater show .99.89%
concordance with SNP Chip data. The targeted regions included
the exons of 17,134 genes and total 36,025,890 bases in the human
genome. We successfully sequenced 92%–94% of targeted regions
to an average depth per individual of 84–98 fold redundancy on
the autosomes, 90%–94% of targeted regions and 57-93 fold
redundancy on the X-chromosomes and 66%–68% of targeted
regions and 45-51 fold redundancy on the Y chromosome in
males. Of the total targeted sequence, 24–25 Mb of the genome
corresponded to protein coding exons as per UCSC known gene
annotation (Table S2). This resulted in capturing and sequencing
of 79%–81% of the exome as defined by UCSC known gene
annotations. Our custom protein variation annotation pipeline
annotated an average of 8,585 missense and 87 termination
changes per individual. Our annotation of cSNVs (coding single
nucleotide variants) was based on UCSC all known genes. A
number of filtering and prioritization steps were applied to reduce
the number and to identify potentially pathogenic mutations,
similar to the methods used in previous studies [28,29]. Missense
variants were sorted by the degree of severity of functional
disruption prediction using CDPred. Variants detected in dbSNP
(version 130) and in eight HapMap exome data were excluded
from being potential disease causing cSNVs [29]. Imposing the
requirement to satisfy all of the above three filters for severity of
amino acid substitution, and not being a common variant resulted
in 483-636 potential protein affecting variants (Table S2). Based
on the inheritance pattern of the disease we required the variants
to follow a Mendelian autosomal recessive pattern of inheritance,
the homozygous subset of which yielded two potential genes
(AFG3L2, DMGDH) (Table S3).
Site-directed mutagenesis and yeast complementation
Wild-type or mutant variants of mature human AFG3L2 and
human SPG7 were fused to the mitochondrial targeting sequence
of the yeast m-AAA protease subunit Yta10 [17]. The human
AFG3L2 gene was mutagenized in yeast expression constructs
using the QuikChange XL Site-Directed Mutagenesis Kit
(Agilent). Mutations were verified by DNA sequencing. Mutant
variants were co-expressed from the multicopy vector YEplac111
under the control of the ADH1 promoter in Dyta10Dyta12 yeast
cells (YKO200)[30]. Yeast cells were grown under standard
growth conditions at 30uC either in YP medium [1% (w/v) yeast
extract, 2% (w/v) peptone] or minimal medium [0.67% yeast
nitrogen base, 0.15% amino acid mix] supplemented with 40 mg/
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60 mg/ml of leucine, and 30 mg/ml lysine in different combina-
tions, both containing 2% (w/v) glucose or for isolation of
mitochondria 2% (w/v) galactose and 0.5% (w/v) lactate. To test
for respiratory chain activity, yeast cells were grown on YP
medium containing 3% (w/v) glycerol as the sole carbon source.
Expression of the human m-AAA protease subunits and processing
of MrpL32 was assessed by immunoblotting using m-AAA protease
and MrpL32-specific antibodies.
Yeast mitochondrial isolation and BN-PAGE
The following procedures were performed as described
previously: Yeast mitochondria isolation [31]; yeast BN-PAGE
analysis [32]. BN-PAGE on human fibroblasts was performed as
previously described using digitonin as detergent (detergent to
protein ratio was 2:1 [w/w]) [33].
Cell transfection
(Figure S1) The coding region of murine Afg3l2 (GenBank/
EMBL/DDBJ accession no. NM_027130) was cloned into the
SfiI-EcoRV sites of the vector pcDNA3.1 in frame with HA. The
Y615C mutation (corresponding to the human Y616C) was
introduced by site-directed mutagenesis.
To assess targeting of Afg3l2-HA to mitochondria, HeLa cells
were co-transfected with a mitochondrially-targeted variant of
GFP (Su9-GFP) and Afg3l2-WT or Afg3l2-Y615C constructs
using Lipofectamine 2000 (Invitrogen). After 48 hours, cells were
collected, fixed with PFA4%/PBS and immunofluorescence was
performed as previously described (Errico et al. 2000). AFG3L2
was detected using specific antibodies (1:200). Immunofluores-
cences were examined and images acquired using an Axioplan
microscope equipped with an Apotome system (Zeiss).
Supporting Information
Figure S1 Immunofluorescence analysis of HeLa cells co-
transfected with wild-type murine Afg3l2 or the mutant variant
Y615C and a mitochondrially-targeted GFP construct (Su9-GFP).
Both wild-type and mutant AFG3L2 proteins localize to
mitochondria after overexpression.
(TIF)
Table S1 Sequencing details of targeted exomes of four
individuals in a single family.
(DOC)
Table S2 Statistics of number of protein changing variants
detected and various filters applied to not consider common and
benign protein coding variation. * NS : Non-synonymous.
** Genotype calls with MPG score $10; (% of Exome
(30,716,913); UCSC).
{ HapMap8 : Coding variation from 8
HapMap Exomes
25.
{{Damaging prediction by CDPred (very
relaxed threshold).
(DOC)
Table S3 Number of genes detected with the application of
homozygous recessive inheritance model.
(DOC)
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